Mequinol 2%/tretinoin 0.01% topical solution for the treatment of melasma in men: A case series and review of the literature

Wellington Regional Medical Center, Florida, USA.
Cutis; cutaneous medicine for the practitioner (Impact Factor: 0.72). 03/2008; 81(2):179-83.
Source: PubMed


Melasma is a common hyperpigmentation disorder that typically affects women, though up to 10% of white individuals seeking treatment for melasma are men. Melasma can be a source of embarrassment for men because of its association with women and pregnancy. We performed a case series assessing the use of mequinol 2%/ tretinoin 0.01% topical solution in 5 men with melasma. Four of 5 patients achieved complete clearance of melasma at 12 weeks, and 1 patient showed moderate improvement. Side effects were minimal and consisted of stinging in one patient. All patients maintained results at the 16-week follow-up visit. Mequinol 2%/tretinoin 0.01% topical solution was an effective and well-tolerated treatment of melasma in men. The vehicle resulted in good compliance and minimal adverse effects in patients. This is the first report describing the use of mequinol 2%/tretinoin 0.01% topical solution for the treatment of melasma in men; there are no reports in women.

24 Reads
  • Source
    • "The formation of quinones results in pigment cell destruction and skin depigmentation [10,57]. The combination of 0.01% tretinoin with mequinol has been reported to inhibit melanin production and has been shown to be effective and safe in the treatment of solar lentigenes and related hyperpigmentation [48,50,58,59]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Skin pigmentary abnormalities are seen as aesthetically unfavorable and have led to the development of cosmetic and therapeutic treatment modalities of varying efficacy. Hence, several putative depigmenting agents aimed at modulating skin pigmentation are currently being researched or sold in commercially available products. In this review we will discuss the regulation of processes that control skin complexion coloration. This includes direct inhibition of tyrosinase and related melanogenic enzymes, regulation of melanocyte homeostasis, alteration of constitutive and facultative pigmentation and down-regulation of melanosome transfer to the keratinocytes. These various processes, in the complex mechanism of skin pigmentation, can be regulated individually or concomitantly to alter complexion coloration and thus ameliorate skin complexion diseases.
    Full-text · Article · Sep 2009 · International Journal of Molecular Sciences
  • Source
    • "Side effects were minimal and consisted of stinging in one patient. All patients maintained results at the 16-weeks' follow-up visit.[38] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Melasma is a common hypermelanotic disorder affecting the face that is associated with considerable psychological impacts. The management of melasma is challenging and requires a long-term treatment plan. In addition to avoidance of aggravating factors like oral pills and ultraviolet exposure, topical therapy has remained the mainstay of treatment. Multiple options for topical treatment are available, of which hydroquinone (HQ) is the most commonly prescribed agent. Besides HQ, other topical agents for which varying degrees of evidence for clinical efficacy exist include azelaic acid, kojic acid, retinoids, topical steroids, glycolic acid, mequinol, and arbutin. Topical medications modify various stages of melanogenesis, the most common mode of action being inhibition of the enzyme, tyrosinase. Combination therapy is the preferred mode of treatment for the synergism and reduction of untoward effects. The most popular combination consists of HQ, a topical steroid, and retinoic acid. Prolonged HQ usage may lead to untoward effects like depigmentation and exogenous ochronosis. The search for safer alternatives has given rise to the development of many newer agents, several of them from natural sources. Well-designed controlled clinical trials are needed to clarify their role in the routine management of melasma.
    Full-text · Article · Mar 2009 · Indian Journal of Dermatology
  • Source
    • "1h-Indene, 1-chloro-2,3- dihydro-is used to produce drug " clidanac " which functions as antiinflammatery analgesic [23]. Mequinol is the key constituent of special cosmetic or medicine applicable to the depigmentation of skin [24]. Benzaldehyde, 3,4,5-trimethoxy- is used as synergist and the pharmaceutical intermediate of antibacterial potentiating agent (TMP). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Bamboo is the important resource for the sustainable development of Chinese forestry. The researches on the extracts of bamboo were mainly focused on the leaf, bark, shoot and distillate, however, the components of bamboo root extract is unresolved though it has the effect to cure some intractable diseases. Therefore, pyrolysis-GC/MS technology was used to identify and analyze the top value-added biomedical and bioactive components of benzene/ethanol extract of Moso bamboo root. The extract was pyrolyzed at 750 °C in helium atmosphere, and then the pyrolyzate was analyzed by online-linked GC/MS. Relative content of each component was determined by area normalization. 69 compounds representing 99.14% were identified from 74 peaks, and the main components were as: 1,3-benzodioxole, 5-(2-propenyl)-(6.83%), 1,2-benzenedicarboxylic acid, bis(2-methylpropyl) ester (6.02%), phenol, 2,6-dimethoxy-(5.03%), 4.2.2 propella-2,4,7,9-tetraene (4.82%), benzofuran, 2,3-dihydro-(4.39%), phenol, 2,6-dimethoxy-4-(2-propenyl)-(total 4.24% from 3 peaks), 3',5'-dimethoxyacetophenone (4.05%), benzoic acid, butyl ester (3.48%), benzene, 1,2-dimethoxy-4-(2-propenyl)-(3.02%), mequinol (2.95%), eugenol (2.79%), etc. The result showed that the pyrolyzate of benzene/ethanol extract of Moso bamboo root is rich in biomedical components, and also contains some bioactive components which can be used as top value-added materials of high-grade spice, cosmetic, food, and chemical.
    Preview · Article ·
Show more